Verus Capital Partners LLC Acquires 12,750 Shares of Organon & Co. (NYSE:OGN)

Verus Capital Partners LLC raised its holdings in shares of Organon & Co. (NYSE:OGN) by 32.5% during the fourth quarter, HoldingsChannel reports. The fund owned 51,943 shares of the company’s stock after purchasing an additional 12,750 shares during the quarter. Verus Capital Partners LLC’s holdings in Organon & Co. were worth $775,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of OGN. Prospera Private Wealth LLC bought a new position in shares of Organon & Co. in the third quarter worth $25,000. Horizon Bancorp Inc. IN lifted its holdings in Organon & Co. by 2,401.5% during the 4th quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock worth $25,000 after purchasing an additional 1,585 shares in the last quarter. Versant Capital Management Inc boosted its stake in Organon & Co. by 92.2% in the 4th quarter. Versant Capital Management Inc now owns 2,760 shares of the company’s stock worth $41,000 after purchasing an additional 1,324 shares during the period. MassMutual Private Wealth & Trust FSB grew its holdings in Organon & Co. by 32.4% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company’s stock valued at $41,000 after buying an additional 672 shares in the last quarter. Finally, WFA Asset Management Corp bought a new stake in shares of Organon & Co. during the fourth quarter valued at about $68,000. Institutional investors own 77.43% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on OGN shares. Barclays cut their price objective on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. TD Cowen upgraded shares of Organon & Co. to a “hold” rating in a research report on Wednesday, January 15th. Finally, Morgan Stanley lowered their price objective on Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating on the stock in a research report on Friday, February 14th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $20.80.

Organon & Co. Trading Down 0.9 %

Shares of Organon & Co. stock opened at $14.91 on Friday. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21. Organon & Co. has a 1 year low of $13.87 and a 1 year high of $23.10. The firm has a market cap of $3.84 billion, a PE ratio of 4.48, a PEG ratio of 0.90 and a beta of 0.76. The company has a 50 day simple moving average of $15.44 and a two-hundred day simple moving average of $17.14.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. The company had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.57 billion. Analysts expect that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 13th. Stockholders of record on Monday, February 24th will be issued a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.51%. The ex-dividend date is Monday, February 24th. Organon & Co.’s payout ratio is currently 33.63%.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.